|
January 2019
Coverage for some diabetes drugs changing, starting Jan. 1
Our goal at Blue Cross Blue Shield of Michigan and Blue Care Network is to provide our members with safe, high-quality prescription drugs while also controlling costs. To accomplish this, we’re making coverage changes to some diabetes drugs (see tables below).
To discuss treatment options with their doctors, we’ll let members fill their current prescriptions through Feb. 28, 2019. If members fill their prescriptions on or after March 1, 2019, it will cost more or will no longer be covered.
Members who have an approved prior authorization for any of the drugs listed below can continue to fill their prescriptions until the prior authorization end date, but may have a higher copayment.
Drug that will have a higher copayment, starting Jan. 1, 2019:
Drug class: Insulins |
Nonpreferred drug |
Member cost |
Preferred alternatives |
Basaglar® Kwikpen U-100 |
Nonpreferred brand copayment |
Lantus® (all forms)
Levemir® (all forms)
Toujeo® (all forms)
Tresiba® Flextouch® |
Drugs we won’t cover, starting Jan. 1, 2019:
Drug class: Glucagon-like peptide-1 (GLP-1) receptor agonists |
Excluded drugs |
Member cost starting March 1, 2019 |
Preferred alternatives |
Bydureon® (all forms)
Byetta® |
Full cost |
Ozempic®
Trulicity®
Victoza® |
Drug class: Dipeptidyl peptidase 4 (DPP-4) inhibitors |
Excluded drugs |
Member cost starting March 1, 2019 |
Preferred alternatives |
Alogliptin**
Onglyza®
Nesina® |
Full cost |
Januvia®
Tradjenta® |
Drug class: Dipeptidyl peptidase 4 (DPP-4) inhibitors combinations |
Excluded drugs |
Member cost starting March 1, 2019 |
Preferred alternatives |
Alogliptin/metformin**
Alogliptin/pioglitazone**
Kazano®
Kombiglyze®
Oseni®
Steglujan® |
Full cost |
Glyxambi®
Janumet®
Janumet® XR
Jentadueto®
Jentadueto® XR
Qtern® |
**These aren’t generic drugs. These are considered brand-name drugs and don’t have generic equivalents. |
